Chronic Lymphocytic Leukemia
The latest news, research, and perspectives in chronic lymphocytic leukemia (CLL). The most common leukemia subtype among adults, CLL occurs when an acquired mutation causes bone marrow to produce abnormal lymphocytes. As these leukemic cells proliferate, the disorder is associated with lymphadenopathy, splenomegaly, and cytopenias.
Advertisement
Advertisement
Adam Kittai, MD, shares recent studies in CLL he is most excited about, including the AMPLIFY and TRANSCEND 004 trials.
The several considerations involved with these agent classes make discussions with patients of treatment decisions crucial.
BTKi/BCL2i combinations may change how CLL treatment is offered over a patient’s lifespan, said Kerry Rogers, MD.
David Russler-Germain, MD, PhD, joins the hosts of “Blood Cancer Talks” to highlight research in lymphoma and CLL.
Therapy also in development for T-cell acute lymphoblastic leukemia, chronic lymphocytic leukemia, and mantle cell lymphoma.
The single-slide test helps clinicians differentiate more than 60 subtypes of these diseases from normal immune response.
The IPS-E, CR0, AIPS-E, CLL-IPI, and Barcelona-Brno risk scores can predict time to first treatment in CLL patients.
Jeff P. Sharman, MD, discusses pivotal findings from the phase III BRUIN CLL-321 trial.
Jeff P. Sharman, MD, explores unmet needs, prognosis, and novel treatments like pirtobrutinib in CLL.
The US cancer mortality rate has declined by 34%, but the incidence of leukemia and other malignancies is increasing.
Extended follow-up was conducted for 652 patients with relapsed or refractory CLL or SLL in the ALPINE study.
PFS and safety findings continued trends seen in prior results at 26.2 months and 43.7 months of median follow-up.
Issues addressed include mandatory versus optional biopsy, informed consent, and safety in both adult and pediatric patients.
The research projects aim to improve patient quality of life, address treatment disparities, and increase access to care.
First-line, fixed-duration ibrutinib plus venetoclax provides durable PFS and OS for patients with CLL.
Venetoclax plus obinutuzumab demonstrates superior safety and efficacy compared with FCR and BR in untreated CLL.
Fewer patients in the acalabrutinib group experienced treatment-emergent cardiovascular medical events after BTKi initiation.
Results observed in the phase 3 AMPLIFY provide evidence for the all-oral approach to CLL treatment.
Blood Cancers Today delivers the latest news, education, and information relevant to hematologic oncology patients and practices.
Sign up to receive Blood Cancers Today eNewsletters:
Advertisement
Section Editor
Alexey V. Danilov, MD, PhDCo-Director of the Toni Stephenson Lymphoma Center | City of Hope National Medical Center
Advertisement
Latest News
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.